认知行为疗法联合齐拉西酮治疗精神分裂症的临床观察

The Clinical Effects of Cognitive Behavior Therapy Combined with Ziprasidone in the Treatment of Schizophrenia

目的观察分析认知行为疗法联合齐拉西酮治疗精神分裂症的效果。方法选取我院精神分裂症患者98人,将他们分成实验组和对照组。实验组患者采取认知行为疗法联合齐拉西酮治疗疾病,对照组患者单纯采取齐拉西酮治疗疾病,对比观察两组患者的依从性以及临床疗效。结果对比观察发现实验组患者拒绝1例、被动执行9例,明显低于对照组患者,实验组患者依从性39例,明显高于13例对照组患者,均具有统计学意义(P<0.05)。经过一段时间治疗后,实验组患者总有效率(91.84%)明显高于对照组(59.18%),差异具有统计学意义(P<0.05)。结论精神分裂症是一组病因未明的重性精神病,临床治疗中采取口服齐拉西酮联合认知行为疗法可以明显提高临床疗效以及患者的依从性。

Objective To observe and analyze the effect of cognitive behavior therapy combmed with zlprasldone mttle treatment of schizophrenia. Methods 98 schizophrenia patients were chosen from our hospital, and they were divided into the experimental group and the control group. The experimental group patients were treated with cognitive behavior therapy combined with ziprasidone, while patients in the control group were only treated by ziprasidone. Thus comparative observation of compliance of the two groups of patients and clinical effect were made. Results It was found out that in the comparative observation that 1 patient of the experimental group refused the treatment, and 9 cases passively implementing, which was significantly lower than that of the control group. There are 39 cases of compliance in the experimental group, which was significantly higher than that of the control group （13 cases）. All these figures have statistical significance （P 〈0.05）. After a period of treatment, the total effective rate of the patients （91.84%） in the experimental group was significantly higher than the control group （59. 18% ）. Such difference was also statistically significant （P 〈 O. 05 ）. Conclusion Schizophrenia is a kind of serious mental disease with unknown causes. Clinical treatment of combining oral zl- prasidone with cognitive behavioral therapy can significantly improve the clinical efficacy and patient compliance.